Page results
-
Our staff have rated UCLH as the top trust in England, improving on our ranking from last year when we were third best in England and top in London.
-
This information is intended for patients who are receiving GnRH-a injections as part of their treatment at UCLH.
-
UCLH is the first site in the UK to open in a world-first trial for people living with progressive forms of multiple sclerosis.
-
This has been written by the Adult Allergy Clinic team at the Royal London Hospital for Integrated Medicine. It is intended for patients (or their family or carers) who may be referred to this clinic.
-
Today we are launching the new UCLH strategy for 2023-2027. Developed with staff, patients and key partners, the strategy sets the future direction of UCLH over the next five years.
-
UCLH research manager Sarah Taylor has won a national leadership award for her work to develop and train research staff.
-
In partnership with Camden MSK, our department has agreed to provide ultrasound-guided cervical (neck) and lumbar (lower back) facet joint injections to patients referred by the Camden community MSK services.
-
In partnership with Camden MSK, our department has agreed to provide ultrasound-guided cervical (neck) and lumbar (lower back) nerve root injections to patients referred by the Camden community MSK services.
-
The research was led by UCLH Director of Research Professor Bryan Williams.
-
Information for patients undergoing VATS for drainage of air or fluid, pleural biopsies and talc pleurodesis.
File results
-
-
-
-
FOI2017123 Information on the price paid, total expenditure and total volume held of Cyanide antidotes, Levothyroxine and Primidone medications
-
FOI/2021/0438 - Dermatology service costs and contract values
-
FOI/2021/0556 - Artworks purchased and held and their value (2018 - 2021)
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0275 - Biologic medications within dermatology
-
FOI/2022/0576 - Medications within dermatology